The Department of Urology is at the forefront of research and medical advancements in prostate cancer.
A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. Ross AE, Hurley PJ, Tran PT, Rowe SP, Benzon B, Neal TO, Chapman C, Harb R, Milman Y, Trock BJ, Drake CG, Antonarakis ES. Prostate Cancer Prostatic Dis. 2020 Mar;23(1):184-193.
CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer. Faisal FA, Murali S, Kaur H, Vidotto T, Guedes LB, Salles DC, Kothari V, Tosoian JJ, Han S, Hovelson DH, Hu K, Spratt DE, Baras AS, Tomlins SA, Schaeffer EM, Lotan TL. Clin Cancer Res. 2020 Jan 22.
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy. Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, Sagar V, Luan Y, Chalmers ZR, Unno K, Mok H, Vatapalli R, Yoo YA, Rodriguez Y, Kandela I, Parker JB, Chakravarti D, Mishra RK, Schiltz GE, Abdulkadir SA. Cancer Cell. 2019 Nov; 36(5): 483-497.e15.
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, Davicioni E, Ross AE, Den RB, Nguyen PL, Feng FY, Lotan TL, Chinnaiyan AM, Schaeffer EM. Clin Cancer Res. 2019 Nov 15;25(22):6721-6730.
Inflammatory Bowel Disease and the Risk of Prostate Cancer. Burns JA, Weiner AB, Catalona WJ, Li EV, Schaeffer EM, Hanauer SB, Strong S, Burns J, Hussain MHA, Kundu SD. European Urology. 2019 May; 75(5): 846-852.
Does prostate volume correlate with Vitamin D deficiency among men undergoing prostate biopsy? Murphy AB, Nyame YA, Batai K, Kalu R, Khan A, Gogana P, Dixon M, Macias V, Kajdacsy-Balla A, Hollowell CMP, Catalona WJ, Kittles R. Prostate Cancer and Prostatic Diseases. 2017 Mar; 20(1): 55-60.
Associations between serum Vitamin D and adverse pathology in men undergoing radical prostatectomy. Nyame YA, Murphy AB, Bowen DK, Jordan G, Batai K, Dixon M, Hollowell CMP, Kielb S, Meeks JJ, Gann PH, Macias V, Kajdacsy-Balla A, Catalona WJ, Kittles R. Journal of Clinical Oncology. 2016 Apr; 34(12): 1345-1349.
Our comprehensive prostate cancer program offers ppersonalized, integrative and innovative care for the diagnosis, treatment and management of prostate cancer. Housed within the Polsky Urologic Cancer Institute, we offer a multidisciplinary access point for prostate cancer treatments, such as surgery, chemotherapy and radiation, as well as resources, including genetic counseling and nutritional guidance. Bolstering promising, active research while strengthening advanced tracking and diagnostic techniques, we offer precision diagnosis and treatment, groundbreaking innovation in treatment and prevention and sustained wellness beyond diagnosis and treatment through our survivorship and follow-up care services.
Shilajit Kundu, MD
Chief of Urologic Oncology in the Department of Urology
Associate Professor of Urology